Ezetimibe Sandoz

Adjunctive therapy to diet for reduction of elevated total cholesterol (total-C), LDL-C & Apo-B in patients w/ primary (heterozygous familial & non-familial) hypercholesterolaemia as monotherapy or in combination w/ statins; for reduction of elevated total-C, LDL-C, Apo B & non-HDL-C in patients w/ mixed hyperlipidemia in combination w/ fenofibrate. Adjunctive therapy to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable in patients w/ homozygous familial hypercholesterolaemia (HoFH). Adjunctive therapy to diet for reduction of elevated sitosterol & campesterol levels in patients w/ homozygous familial sitosterolaemia (phytosterolemia).

Monotherapy or in combination w/ statin or fenofibrate 10 mg once daily. Concomitant use w/ bile acid sequestrant Dosing should occur either ≥2 hr before or ≥4 hr after bile acid sequestrant administration.

May be taken with or without food.

Hypersensitivity. In combination w/ statin: Active liver disease or unexplained persistent elevations in serum transaminases. In combination w/ statin or fenofibrate: Woman w/ childbearing potential. Pregnancy & lactation.

Dyslipidaemic Agents

C10AX09 - ezetimibe ; Belongs to the class of other lipid modifying agents.

POM